Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma

ConclusionNivolumab plus ipilimumab had modest efficacy for papillary renal cell carcinoma compared with that for clear cell renal cell carcinoma. Nivolumab plus ipilimumab remains an option for a limited number of patients with intermediate- or poor-risk papillary renal cell carcinoma.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research